Evidence Supports CAR T-Cell Therapy Against Gastric and Brain Tumors, ASCO 2025 Presentations Show

New studies presented at the American Society of Clinical Oncology (ASCO) 2025 annual meeting in Chicago have provided promising evidence of the effectiveness of CAR T-cell therapy in treating gastric and brain tumors.

Held from May 30 to June 3, the conference showcased groundbreaking research, with papers published in leading journals such as The Lancet and Nature Medicine.

CAR T-cell therapy is an innovative cancer treatment that involves genetically modifying a patient’s own T-cells—a critical component of the immune system—to better recognize and attack cancer cells.

The latest findings mark important progress in expanding the application of this therapy beyond blood cancers to solid tumors, offering hope for improved outcomes in patients with challenging gastric and brain cancers. Researchers continue to explore the therapy’s potential to revolutionize cancer treatment.